Hims & Hers Health (NYSE:HIMS) Insider Sells $691,808.05 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 25,111 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total value of $691,808.05. Following the sale, the insider directly owned 313,964 shares in the company, valued at $8,649,708.20. This trade represents a 7.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Price Performance

Shares of HIMS traded up $0.86 on Thursday, reaching $31.95. The stock had a trading volume of 18,861,192 shares, compared to its average volume of 26,241,924. The firm has a market capitalization of $7.45 billion, a PE ratio of -50.71 and a beta of 2.40. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The firm has a 50-day moving average of $32.17 and a 200 day moving average of $26.05. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $65.30.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.17 earnings per share. Sell-side analysts expect that Hims & Hers Health, Inc. will post -0.05 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB increased its position in Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after buying an additional 319 shares in the last quarter. Sigma Planning Corp lifted its position in shares of Hims & Hers Health by 1.5% in the first quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock valued at $540,000 after acquiring an additional 388 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of Hims & Hers Health by 3.1% in the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock valued at $728,000 after acquiring an additional 443 shares in the last quarter. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health during the third quarter valued at $28,000. Finally, Northwestern Mutual Investment Management Company LLC raised its stake in Hims & Hers Health by 1.1% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 46,607 shares of the company’s stock valued at $1,513,000 after purchasing an additional 521 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of several research reports. JPMorgan Chase & Co. cut their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. TD Cowen increased their price objective on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research note on Tuesday, August 11th. Barclays increased their price objective on shares of Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research note on Wednesday, June 17th. Weiss Ratings restated a “sell (d)” rating on shares of Hims & Hers Health in a report on Friday, August 7th. Finally, UBS Group set a $23.00 target price on shares of Hims & Hers Health in a research report on Friday, May 22nd. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $32.43.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum rejected the FTC’s allegations concerning data privacy, advertising, billing and subscription cancellations, arguing that the agency misunderstands Hims & Hers’ business practices. His comments may be helping ease concerns after the recent regulatory-driven selloff. Hims & Hers rejects privacy allegations
• Positive Sentiment: Analysts remain focused on Hims & Hers’ growth potential, including margin expansion and broader access to care. A recent investment thesis characterized the current margin pressure as a potential buying opportunity, while the CEO said an AI health coach could launch within roughly 12 months and potentially improve medication adherence. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Management’s planned expansion into AI-enabled care, testosterone and peptide treatments could create new growth avenues, but these initiatives remain prospective and do not immediately resolve regulatory or profitability concerns.
• Negative Sentiment: The FTC lawsuit remains the central overhang. It alleges improper handling of private health data and potentially deceptive billing and cancellation practices. Multiple law firms, including Kaplan Fox, Berger Montague and Kessler Topaz, have announced investigations that could increase legal costs, compliance requirements and potential securities-liability exposure. Kaplan Fox investigation
• Negative Sentiment: Recent earnings showed strong revenue growth of 38.2% year over year and revenue above expectations, but the company posted a substantially larger-than-expected loss. The $0.37 adjusted loss per share versus a $0.05 consensus loss highlights investor concerns about margins and execution.
• Negative Sentiment: Several executives reported stock dispositions, including sales by the CEO, CFO and CTO. Most were nondiscretionary share withholdings or sales under Rule 10b5-1 plans to cover taxes on vested equity, limiting their value as a confidence signal but still adding a modest supply-related overhang. SEC insider transaction filing

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.